key: cord-0780077-x5p8lqq1
authors: Da, Yi; Goh, Giap Hean; Khatri, Priyanka
title: A Case of Membranous Nephropathy Following Pfizer-BioNTech mRNA vaccine against Coronavirus 2019
date: 2021-07-30
journal: Kidney Int
DOI: 10.1016/j.kint.2021.07.016
sha: b56844b7e646b307043faf1fecfac353c3a41b9a
doc_id: 780077
cord_uid: x5p8lqq1

nan

To the Editor: We read recent report describing the relapse of membranous nephropathy (MN) following inactivated vaccine against Coronavirus 2019 (COVID-19) 1 . Here, we describe a case of new onset MN following Pfizer-BioNTech mRNA based COVID-19 vaccine.

A 70-year-old man with no past medical history was referred to our institution for generalized edema, which happened a week after his first dose of Pfizer-BioNTech vaccine and got worse a day after the second dose which was scheduled 3 weeks apart. He denied other symptoms. On examination, his blood pressure was 155/86mmHg, and he had bilateral pitting edema up to his thighs. Laboratory tests revealed serum creatinine of 114μmol/L, albumin 17g/L, total cholesterol of 9.24mmol/L, 17 Red Blood Cells/μL in urine analysis, and 24-hour total urine protein of 4.4 gram. Secondary causes including drugs and infections (Hepatitis B, Hepatitis C, HIV) were excluded. He was found to have IgM kappa monoclonal gammopathy of undetermined significance. A thorough malignancy screening including enhanced CT thorax, abdomen, and pelvis, gastroscope plus colonoscope, and prostate-specific antigen was not yielding.

A percutaneous kidney biopsy was performed, and diagnosis of MN was confirmed. The results are shown in Figure 1 .

Serum anti-phospholipase A2 receptor (PLA2R) was negative and kidney biopsy stained negative for PLA2R antigen as well. Serum Thrombospondin type-1 domain-containing 7A (THSD7A) antibody was positive by indirect immunofluorescence assay. The SARS-CoV-2 spike protein antibody was 147.0U/mL three months after his second dose of vaccine. The patient is currently being managed with Irbesartan, frusemide and warfarin. There are no signs of spontaneous remission after two months.

Our observation, together with other case reports of MN development post COVID-19 infection 2,3 and MN relapse post COVID-19 vaccine 1 , supports a possible immune dysregulation process causing loss of tolerance to certain podocyte antigens, which requires further studies to elucidate.

Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination

COVİD-19 infection in a membranous nephropathy patient treated with rituximab

Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): A case report